The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone. METHODS: We conducted a randomized, double-blind, phase 3 trial to evaluate perioperative pembrolizumab in patients with early-stage NSCLC. Participants with resectable stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned in a 1:1 ratio to receive neoadjuvant pembrolizumab (200 mg) or placebo once every 3 weeks, each of which was given with cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) or placebo once every 3 weeks for up to 13 cycles. The dual primary end points were event-free survival (the time from randomization to the first occurrence of local progression that precluded the planned surgery, unresectable tumor, progression or recurrence, or death) and overall survival. Secondary end points included major pathological response, pathological complete response, and safety. RESULTS: A total of 397 participants were assigned to the pembrolizumab group, and 400 to the placebo group. At the prespecified first interim analysis, the median follow-up was 25.2 months. Event-free survival at 24 months was 62.4% in the pembrolizumab group and 40.6% in the placebo group (hazard ratio for progression, recurrence, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.72; P<0.001). The estimated 24-month overall survival was 80.9% in the pembrolizumab group and 77.6% in the placebo group (P = 0.02, which did not meet the significance criterion). A major pathological response occurred in 30.2% of the participants in the pembrolizumab group and in 11.0% of those in the placebo group (difference, 19.2 percentage points; 95% CI, 13.9 to 24.7; P<0.0001; threshold, P = 0.0001), and a pathological complete response occurred in 18.1% and 4.0%, respectively (difference, 14.2 percentage points; 95% CI, 10.1 to 18.7; P<0.0001; threshold, P = 0.0001). Across all treatment phases, 44.9% of the participants in the pembrolizumab group and 37.3% of those in the placebo group had treatment-related adverse events of grade 3 or higher, including 1.0% and 0.8%, respectively, who had grade 5 events. CONCLUSIONS: Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery. Overall survival did not differ significantly between the groups in this analysis. (Funded by Merck Sharp and Dohme; KEYNOTE-671 ClinicalTrials.gov number, NCT03425643.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given the lack of successful trials in the perioperative space in HCC, no surrogate end point has been validated yet, as is the case for pCR in patients with NSCLC20,120 and breast cancer8.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [120]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although ICI-treatment is approved for the treatment of NSCLC patients in the localized and metastatic setting regardless of PD-L1 status2–4, many patients still fail to achieve clinically meaningful responses.”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Since results from one of the first clinical trials of such a therapeutic approach in patients with NSCLC were reported in 2018 (ref. 19), the efficacy and safety of neoadjuvant ICIs have been firmly established in multiple tumour types, with FDA approvals for two indications (NSCLC20,120 and triple-negative breast cancer8).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citationNeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Self-citationOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citationFelip, E., Altorki, N. K., Zhou, C., Csőszi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A. V., Akopov, A. L., Martínez‐Martí, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,497
Self-citationNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,430
Flagged first, then by citations
Research works printed but not linked: 2
- Brierly JD Gospodarowicz MK Wittekind C. TNM classification of malignant tumors. 8th ed. New York: John Wiley 2016.
- Heymach JV Harpole D Mitsudomi T et al. AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. In: Proceedings and Abstracts of the 114th Annual Meeting of the American Association for Cancer Research April 14–19 2023. Orlando FL: American Association for Cancer Research 2023. abstract.
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Dörr-Jerat, N. M. (2025) · Journal of Surgery Research and Practice · doi:10.46889/jsrp.2025.6302
Current landscape of immunotherapy for CNS tumors
Landry, A., Dunn, G. P., & Lim, M. K. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf118
Definitive Proton Beam Therapy for Second Primary Non–small Cell Lung Cancer After Pneumonectomy
Nakamura, M., Ohnishi, K., Okumura, T., Fujioka, D., Baba, K., Murakami, M., Mizumoto, M., Sekine, I., Inagaki, M., Sato, Y., et al. (2025) · International Journal of Particle Therapy · doi:10.1016/j.ijpt.2025.101202
Fenesan, M. P., Sîrbu, E., & Iana, A. (2025) · Cureus · doi:10.7759/cureus.92171
Marcellusi, A., Belfiore, M., Tempre, R., Buonfiglio, M., & Russo, A. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01469-0
Liu, W., Sui, Z., Wang, C., Deng, Y., Cai, S., Jia, R., Yu, Z., Kang, M., & Zhang, B. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1679782
Multilevel Drivers of Disparities in Cardio-Oncology
McCrohan, M., Busby, T., Quiroga, D. M., Branch, M. E., Sutton, A. L., Brown, S.-A. N., Ganatra, S., Ghazi, S. M., Kola-Kehinde, O. O., Ferdousi, M., et al. (2025) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-031-97517-2_2
Ugalde, P. A., Lacroix, V., & Schil, P. E. V. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.09.009
Igai, H., Ida, A., Numajiri, K., Nii, K., & Kamiyoshihara, M. (2025) · Annals of Thoracic Surgery Short Reports · doi:10.1016/j.atssr.2025.09.002
Salomone, F., Novero, G., Ciani, O., Ferrara, R., Servetto, A., Florez, N., Maïo, M. D., Pravettoni, G., & Pompili, C. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf339
Slomka, J., Eberst, G., Westeel, V., & Wislez, M. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00066-7
Quand et comment réaliser un staging ganglionnaire ?
Basille, D. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00063-1
Çetinkaya, Ç., Keskın, S., Öztürk, M. A., Saglam, E. K., Yaman, M., Yıldızeli, B., & Batırel, H. F. (2025) · Journal of Minimal Access Surgery · doi:10.4103/jmas.jmas_93_25
Interstitial pneumonia microenvironment promotes metastasis to the mediastinal lymph nodes and lungs
Maeda, R., Inomata, M., & Yamada, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1657948
Lou, H., Cui, S., Dong, Y., Liu, S., Li, S., Song, H., & Zhao, X. (2025) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/0115734056404160250925115913
CDA-AMC (2025) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2025.1264
Liebowitz, A., Posawatz, D., & Wiener, D. C. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.07.011
Kakuwa, T., Naka, G., Watanabe, T., Ishii, T., Ichinose, Y., & Higashi, T. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03025-y
A Paradigm Shift in Perioperative Treatment for Lung Cancer
Azuma, Y. (2025) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.86.463
Malik, P. S., Baral, R. P., Chugh, B., Dawoud, E. A., Forde, P. M., Ghosn, M. G., Jabbar, A. A., Jiwnani, S. S., Kapu, V., Kumar, K. S., et al. (2025) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_15_25
Visual analysis of global research on neoadjuvant and adjuvant strategies in NSCLC from 2013 to 2023
Zhang, T., Hu, S., Yang, W., Zhang, J. J., Wei, W., Dai, W., Cai, M., Li, Q., Xiao, Z., & Ma, L. (2025) · International Journal of Radiation Research · doi:10.61882/ijrr.23.3.3
Gil‐Sierra, M. D., Briceño-Casado, M. D. P., & Moreno-Ramos, C. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.10.006
Priming for Cure: How Perioperative Immunotherapy Is Redrawing Surgical Boundaries
Ryu, W. K., Lim, J. H., & Ryu, J. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.07.125
Diagnostic yield: what is sufficient?
Matsumoto, Y., & Gonzalez, A. V. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001232
Guay, C.-A., Suhani, A., Perreault, L., Mai, V., Laliberté, A.-S., Labbé, C., & Provencher, S. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.11.004
Schulz, D., Morfouace, M., Fernandez, B. P., Możejko, M., Déglise, S., Daniel, M., Eling, N., Hong, H. S., Tissot, S., Rusakiewicz, S., et al. (2025) · medRxiv · doi:10.1101/2025.11.10.25339890 · Cited by 1
Current landscape of cross-line immune checkpoint blockade for cancer treatment
Fan, P., Wu, K., Zhu, C., & Guan, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218135
Wang, Y., Wang, C., Li, Y., & Jiang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1736267
Guberina, M., Metzenmacher, M., Pöttgen, C., Wiesweg, M., Guberina, N., Merkel‐Jens, A., Luetke‐Brintrup, D., Bölükbas, S., Eberhardt, W., Stamatis, G., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70183
Wang, Y., Dong, Y., Chen, T., Wen, J., Xu, L., Deng, J., She, Y., Wu, J., Chen, Q., Jiang, L., et al. (2025) · JTCVS Open · doi:10.1016/j.xjon.2025.11.008
Kapur, P., Christie, A. L., Jarmale, V. N., Tahmasebi, F., Xie, B., Miyata, J., Rakheja, D., Cadeddu, J. A., Margulis, V., Hammers, H. J., et al. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101069
An Alternative Treatment Effect Measure for Time-to-Event Oncology Randomized Trials
Hutson, A. D., & Yu, H. (2025) · Cancers · doi:10.3390/cancers17233750
Pan, H., Chen, Y., Tian, Y., Chen, H., Ge, Z., Kong, W., Huang, J. Y., Zhou, C., Xu, G., Chen, H., et al. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.109229
Chen, C., & Chen, S. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.07.008
Picón, C. R., Rizzo, M., Puparelli, C., Castagneris, N., Martin, C., Peralta, D., Tsou, F., Enrico, D. H., Viola, A., Okassova, A., et al. (2025) · Oncología Clínica · doi:10.56969/oc.v30i3.215
Schvartsman, G., Amirato, Y. M., Monfardini, F., dos Santos, G. P., Gomes, D. B. D., Koch, L. M., Bibas, B. J., Gomes, O., Campregher, P. V., Severino, P., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100940
WANG, K., Wang, L., Wan, R., & CHEN, H. (2025) · Research Square · doi:10.21203/rs.3.rs-8309670/v1
Pompili, C., Jain, P., Clarke, K., Franks, K., Lodhia, J. V., Nardini, M., Otter, D., Teh, E., Tcherveniakov, P., & Brunelli, A. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.111356
Xu, Y., Li, J., Wang, J., & Deng, F. (2024) · Figshare · doi:10.6084/m9.figshare.26747291
Gong, B., Guo, Y., Li, Y., Wang, J., Zhou, G., Chen, Y.-H., Nie, T., Yang, M., Luo, K., Zheng, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25116068
Xu, Y., Li, J., Wang, J., & Deng, F. (2024) · Figshare · doi:10.6084/m9.figshare.26747294
Li, D., & Zou, Y. (2025) · Frontiers in Surgery · doi:10.3389/fsurg.2025.1722026
Multimodality approach for locally advanced lung cancer: when is surgery most beneficial?
Abdeljalil, R., Al-odwan, A., Alshwayyat, S., Nemrawi, L. O., Hejleh, T. A., rabi, K. A., Yaser, S., Jazar, H. A., Khader, J., Al-Nsour, A., et al. (2025) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-025-03752-9
Tanaka, F., Watanabe, Y., Sugawara, S., Okami, J., Muto, S., Okada, M., Horio, Y., Tsuboi, M., Sato, Y., Takamochi, K., et al. (2025) · Cancer Science · doi:10.1111/cas.70300
Self-citationTreatment Patterns in Early Stage NSCLC in Asia: Findings From the ELEVATE Study
Ahn, M., Tan, D. S. W., Windsor, M. N., Ong, B., Ho, J. C. M., Kim, H. K., Lee, V. H.-F., Hsu, F.-M., Shih, J., Pham, D. N. M., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100945
Gil‐Sierra, M. D., Pizarro-Barron, E., & Briceño-Casado, M. D. P. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.10.018
Kuchevskaya, O. A., Esakov, Y., Туквадзе, З. Г., Покатаев, И. А., Antonova, T. G., Стативко, О. А., Kuzmina, E., Lyadova, M. A., Партс, С. А., Галкин, В. Н., et al. (2025) · Voprosy Onkologii · doi:10.37469/0507-3758-2025-71-6-of-2369
Shamsi, H. A., Abdelwahed, N., Jaafar, H., Ghazal, H., Kourié, H. R., Naim, N., Otsman, S., Bennini, N., Dawoud, E. A., Trad, D., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2610171
20 Years of Breakthroughs: Transforming the Fight Against Thoracic Malignancies
Wang, F., Uprety, D., & Adjei, A. A. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.11.004
Zhang, Y., Song, X., Li, J., Zhao, F., Li, L., Liu, N., Zhao, M., & Yuan, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1503615
Unlocking the potential of immunotherapy for patients with resectable non–small cell lung cancer
Patel, S. P., Gainor, J. F., Kao, S. C.-H., Lee, S.-H., Mok, T. S. K., Shah, R., Zhou, C., & Peters, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1690367
Self-citationChan, B. A., Youlden, D. R., Pattison, A., Guan, T., Cossio, D., & Sanmugarajah, J. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70185
Li, F., Zhang, C., Huang, L., Wang, Z., Ye, G., Gu, Z., & Qi, Y. (2026) · BMC Cancer · doi:10.1186/s12885-026-15582-6
Upfront surgery for clinical N1 stage II non-small cell lung cancer
Watanabe, Y., Uchida, S., Ichinokawa, H., Hattori, A., Fukui, M., Matsunaga, T., Takamochi, K., Tomita, H., & Suzuki, K. (2026) · Surgery Today · doi:10.1007/s00595-026-03235-x
Immunotherapy in uncommon EGFR-mutant NSCLC: Revisiting a therapeutic gray zone
Lim, J. H., Ryu, W. K., & Ryu, J. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.108938
Imaging predictors of pleural response in stage IV non–small cell lung cancer
Zhou, N., Vlahos, I., Hooda, Z., Hofstetter, W. L., Mehran, R. J., Rajaram, R., Rice, D. C., Sepesi, B., Swisher, S. G., Vaporciyan, A. A., et al. (2026) · JTCVS Open · doi:10.1016/j.xjon.2026.101605
Takamochi, K., Suzuki, K., Tsuboi, M., Niho, S., Ishikura, S., Kobayashi, S., Oyamada, S., Yamaguchi, T., Suzuki, H., Ito, H., et al. (2026) · JTCVS Open · doi:10.1016/j.xjon.2026.101607
Self-citationProposal for a Hybrid Anatomical and Biological Staging System in Lung Cancer
Papavassiliou, K. A., & Papavassiliou, A. G. (2026) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2026.01.018
Xu, J., Wang, K., Zhang, G., Liu, X., Zhang, Y., Ren, J., Huang, Y., Song, Z., Ren, F., Wei, T., et al. (2026) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2026.01.030
Liu, Y., Sun, Y., & Chen, N. (2026) · Journal of Visualized Experiments · doi:10.3791/69622
Shibaki, R., Akamatsu, H., Okada, M., Murotani, K., Osuga, M., Nishino, K., Murakami, S., Wakuda, K., Mitsudomi, T., 弘人, 多., et al. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.100967
Successful carinal resection and double-barrel reconstruction after neoadjuvant chemoimmunotherapy
Shigeta, N., Adachi, H., Ito, H., Masuda, H., & Saito, A. (2026) · JTCVS Techniques · doi:10.1016/j.xjtc.2026.102278
Belloir, P., & Messekher, M. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.11.014
Clark, E. A., & Baker, A. P. (2023) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/fvocywg2tc
PEMBROLIZUMAB - REVIEW OF USE AND EFFECTIVENESS IN THE TREATMENT OF SELECTED NEOPLASM
Kulka, K., Król, W., Kafara, Z., Kowalczyk, D., Lechowska, Z., Kafara, A., Szarek, R., Koronczok-Matusiak, J., Michta, K., & Jurczak, D. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4453
Update zur Regressionsgraduierung nichtkleinzelliger Lungenkarzinome
Elsner, F., Löwer-Kiem, L.-M., Fuchs, F., Berezowska, S., & Steinestel, K. (2026) · Die Pathologie · doi:10.1007/s00292-026-01544-z
Daverat, H., Blasco, N., Robert, S., Rovini, A. M. F., Claire Dalmay, A., Lalloué, F., Pothier, A., Durand, K., & Naves, T. (2026) · Biosensors · doi:10.3390/bios16030134
Donin, G., Tichopád, A., Sedlák, V., Rybář, M., Rožánek, M., Mothejlová, K., Koblížek, V., Turčáni, P., Sova, M., Dušek, L., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9362847/v1
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Deng, H.-J., Zhang, J.-B., Ss, L., & Zhao, Z.-R. (2026) · Journal of Visualized Experiments · doi:10.3791/69933
Huang, S., Yuan, C., Wang, Y., Chen, B., Tang, W., Jiang, H., Li, W., Liang, Y., & Huang, W. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-03940-1
Li, X., Wang, S., Qiu, Z., Sun, R., Wang, T., Ren, X., Lv, B., Ma, X., Cheng, L., Liu, Y., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-36534-x
藤岡, 雅., Aranishi, T., Shukuya, T., Araujo, L., Owen, D., Sowers, T., Shirai, Y., Carbone, D. P., & Takahashi, K. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.100977
Hou, X., Guo, Y., Yan, M., Zhang, Y., Zhang, Z., Sun, Y., Ren, K., Li, X., Ding, X., & Zhao, L. (2026) · Radiation Oncology · doi:10.1186/s13014-026-02819-8
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer
Fortman, D. D., & Qin, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1750153
Li, H., Yang, L., Sun, J., Lin, J., Li, W., Tian, P., & Li, Y. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03141-w
Immune checkpoint inhibitor-induced joint involvement
Quelain, J., Henry, J., Belkhir, R., Mariette, X., & Bitoun, S. (2026) · La Presse Médicale · doi:10.1016/j.lpm.2026.104340
BZW1 Drives Immune Evasion in Lung Adenocarcinoma via Ferroptosis Suppression
Zhao, L., Peng, Y., Liang, Q. D., Liu, S., Li, Y., Ma, L., Hu, M., Zheng, S., Liu, Z., & Gao, S. (2026) · Advanced Science · doi:10.1002/advs.202521885
Self-citationWang, Y., Zhang, W., Wang, X., Zhang, H., Mu, Q., Wang, J., Liu, Q., Wang, G., Li, X., & Sun, D. (2026) · Cancers · doi:10.3390/cancers18060955
On Window Mean Survival Time With Interval‐Censored Data
Iijima, T., Momozaki, T., & Ando, S. (2026) · Statistics in Medicine · doi:10.1002/sim.70491
The Role of PD-L1 in Lung Cancer: From Biology to Clinical Application
Lamghari, H., & Karkouri, M. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s591588
He, J., Zhou, Y., Ma, F., Yan, H., Liu, C., Zeng, L., & Liu, X. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004027
Yao, M., Li, W., Wang, Y., Chen, Z., Pan, Y., Zhang, K., Lu, Z., Chen, D., Zheng, Y., & Yang, Y. (2026) · Diagnostic Pathology · doi:10.1186/s13000-026-01778-8
Çağlar, A. A., Hannarici, Z., Büyükbayram, M. E., Turhan, A., Soylu, Y. E., Bilici, M., & Tekin, S. B. (2026) · BMC Cancer · doi:10.1186/s12885-026-15878-7
Nicht-kleinzelliges Lungenkarzinom: Ist geschlechtsspezifische Immuntherapie nötig?
Krieghoff‐Henning, E., Collienne, M., & Loges, S. (2026) · Forum · doi:10.1007/s12312-026-01555-0
Gil‐Sierra, M. D., Pizarro-Barron, E., & Briceño-Casado, M. D. P. (2026) · Farmacia Hospitalaria · doi:10.1016/j.farma.2026.02.017
Advances in Perioperative Immunotherapy for Resectable Non-Small Cell Lung Cancer
柴, 鹏. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1631214
National Delphi consensus on perioperative and locally advanced NSCLC management in Colombia
Bruges, R. E., Lombana, M., Carvajal, C., González, R. Z., Martinez, J. J. O., González-Motta, A., & Salazar, L. M. L. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2653635
Quintanilha, J. C. F., Li, G., Graf, R. P., Gascó, A., Mitchell, J. W., & Huang, R. S. P. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014168
Immunotherapy in resectable non–small cell lung cancer; emerging clinical questions
Mitsudomi, T., Sato, K., Suda, K., & Tomizawa, K. (2026) · International Journal of Lung Cancer · doi:10.1016/j.ijlcan.2026.100024
Murakami, K., Shimada, Y., Hamaji, M., Yamanashi, K., Kawaguchi, Y., Kudo, Y., Kayawake, H., Yutaka, Y., Date, H., & Ikeda, N. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.03.013
Quantitative Assessment of Lung Nodule: Deep Learning and Radiomics
Hwang, E. J., & Goo, J. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-14103-3_20
Cancers associés au VIH : immunogénomique, immunogénicité et immunothérapie
Abbar, B. (2024) · theses.fr (ABES) · doi:10.70675/4f30d250zc7b8z462ez9893z38a97714c288
Issa, W., Sayegh, N., Günenç, D., Kaur, N., DeVilbiss, A., Abdullah, S. A. A., Kapur, P., Courtney, K. D., Hammers, H. J., Brugarolas, J., et al. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102558
Wang, J., Song, P., Ge, Y., Yang, H., Li, S., Ma, R., Ma, T., Feng, S., Zhang, C., Sun, T., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70473
Ma, Z., Wu, Y., Ji, G., Zhou, Z., Wang, X., Wang, J., Liu, W., Deng, L., Wang, W., Yi, J., et al. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70280
Management of borderline resectable NSCLC: a narrative review
Mielgo-Rubio, X., González, S. A., Uribelarrea, E. A., Nadal, S. B., de Juan, V. C., Martín, M. M., Navarro-Martín, A., Castro, R. L., Pulla, M. P., Trujillo-Reyes, J. C., et al. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04305-9
Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer
Caturegli, G., Canavan, M., Ayoade, O. F., Boffa, D. J., & Resio, B. J. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.03.016
Horne, A., Gomez-Randulfe, I., Ford, A., Milton, R. S., Jankowska, P., O'Dowd, E. L., Greystoke, A., & Finn, C. F. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109411
Metadata
- Authors
- Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G. L., Bylicki, O., Rodríguez-Abreu, D., Chaft, J. E., Novello, S., Yang, J., Keller, S. M., Samkari, A., & Spicer, J. D.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- From Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA (H.W.); Centre Hospitalier de l’Université de Montréal (M.L.) and McGill University Health Centre (J.D.S.) — both in Montreal; Kanagawa Cancer Center, Yokohama (T.K.), and National Cancer Center Hospital East, Kashiwa (M.T.) — both in Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (S.-H.L.); the National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (S.G.), and Beijing Cancer Hospital, Peking University (K.-N.C.) — both in Beijing; University Hospitals Leuven, Leuven, Belgium (C.D.); Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas (D.R.-A.) — both in Spain; Zentralklinik Bad Berka, Bad Berka, Germany (E.E.); Sanatorio Parque, Cordoba, Argentina (G.L.M.); Hôpital d’I...
- Memorial Sloan Kettering Cancer Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 491-503
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11074923
- OpenAlex
- W4379209546
- Cited by
- 1,180
- References
- 18
- Citations by year
- 2026: 324 · 2025: 388 · 2024: 368 · 2023: 100
- FWCI
- 216.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Acceda (Universidad de Las Palmas de Gran Canaria) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Merck Sharp and Dohme LLC, a subsidiary of Merck & Co, Inc
- National Cancer Institute (P30 CA008748)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- pembrolizumab, early-stage non-small cell lung cancer, perioperative immunotherapy, PD-1 inhibitors, cisplatin-based chemotherapy, event-free survival, overall survival, pathological response, pathological complete response, N2 disease, resectable lung cancer, treatment safety, immune-related adverse events
- MeSH terms
- Adjuvants, Immunologic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Combined Modality Therapy, Humans, Lung Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
